Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379865 | 0.86 | ESR1 (0.55) | TNFNOD1MAPK1PIP4K2CALDH1A1 | |
| SCHEMBL379503 | 0.83 | TNF (0.50) | TNFNOD1MAPK1PIP4K2CALDH1A1 | |
| SCHEMBL380011 | 0.81 | UTS2R (0.53) | TNFNOD1MAPK1ALDH1A1POLB | |
| SCHEMBL2369019 | 0.81 | MAPK1 (1.00) | TNFNOD1MAPK1PIP4K2CALDH1A1 | |
| SCHEMBL379504 | 0.81 | TNF (0.47) | TNFNOD1MAPK1PIP4K2CALDH1A1 | |
| SCHEMBL379745 | 0.81 | EED (0.49) | TNFNOD1MAPK1ALDH1A1POLB | |
| SCHEMBL4946829 | 0.80 | PDE11A (0.49) | TNFNOD1MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL379757 | 0.78 | CCNC (0.47) | TNFNOD1MAPK1L3MBTL1AURKB | |
| SCHEMBL379602 | 0.78 | PDE11A (0.47) | TNFNOD1MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL2900101 | 0.78 | TNF (0.69) | TNFNOD1MAPK1PIP4K2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | claimed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | claimed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | claimed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | claimed |
| US-9216992-B2 | Thieno[3,2-c]pyridine potassium channel inhibitors | XENTION LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | disclosed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161672-A1 | Compounds | KCNJ2, KCNT1, KCNT2 | TNF 953/4885NOD1 141/4885MAPK1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.